The Relationship of 25(OH)D3 with Diabetes Mellitus and the Mediation Effect of Lipid Profile in Chinese Rural Population of Henan Province.

Background and Objectives: Studies suggest that vitamin D is involved in the development of type 2 diabetes mellitus (T2DM) and influences serum lipids levels, while lipid disorders are also closely related to T2DM. This study attempts to explore the complex relationship of serum 25(OH)D3, serum lipids, and T2DM among Chinese population. Materials and Methods: A cross-sectional study was carried out among 2326 subjects. The chi-square (χ2) test was applied to compare the prevalence of T2DM or dyslipidemia between two serum 25(OH)D3 levels. Linear regression was applied to analyze the correlation between serum lipids and 25(OH)D3 contents. Univariate and logistic analysis were used to explore the relationship between two lipid levels and T2DM. Mediation analysis was used to explore whether serum lipids mediate the relationship between two serum 25(OH)D3 levels and T2DM. Results: Compared to subjects with 25(OH)D3 ≥ 30 ng/mL, subjects with 25(OH)D3 < 30 ng/mL were higher in the prevalence of T2DM. The occurrences of high TG and low HDL-C were significantly higher in vitamin D deficiency and insufficiency than those in vitamin D sufficiency. Serum 25(OH)D3 content showed a reverse correlation with TC, TG, and LDL-C, but positive correlation with HDL-C. The odds ratios (ORs) (95% confidence intervals, 95%CI) of T2DM by comparing TG ≥ 2.26 mmol/L vs. TG < 2.26 mmol/L and HDL-C < 1.04 mmol/L vs. HDL-C ≥ 1.04 mmol/L in all participants were 2.48 (1.94-3.18) and 1.37 (1.07-1.75), respectively. Serum TG or HDL-C level partially mediated the relationship between two 25(OH)D3 level and T2DM. Conclusions: Serum 25(OH)D3 < 30 ng/mL seems to be associated with T2DM or dyslipidemia (high TG and low HDL-C) in our study, but there is still no proof of a cause-effect relationship. Moreover, serum TG or HDL-C level partially mediated the relationship between 25(OH)D3 levels and T2DM.

A fluorescent platform integrated with a "one-pot" nicking endonuclease signal amplification and magnetic separation for simultaneous detection of tumor markers.

Although Enzyme-linked immunosorbent assay (ELISA) has been widely used for biomedical research, simultaneous sensitive and cost-effective detection of multiple biomarkers is challenging. Herein, we proposed a "one-pot" nicking endonuclease signal amplification (NESA)-based fluorescent aptasensor for simultaneous detection of carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP). Firstly, two aptamers were synchronously immobilized on the surface of magnetic nanoparticles (MNPs) by coupling with two complementary DNA (cDNA). CEA and AFP specifically recognized the aptamers and then the released cDNA (ssDNA) from the double-strands (dsDNA) triggers NESA, further breaking two detection probes which were labeled with the fluorescent dye (FAM and ROX) and its quencher (BHQ1 and BHQ2) at the same time. Then, the fluorescence signal of FAM and ROX were restored separately. The results indicated that the fluorescence intensity at the emission wavelength of 518 nm and 610 nm had a positive correlation with CEA and AFP concentrations, respectively. Under the optimum conditions, wider liner range of 1-500 ng mL-1 to CEA and 5-800 ng mL-1 to AFP of this fluorescent aptasensor were successfully obtained, achieving a detection limit of CEA and AFP were 0.7 ng mL-1 and 2 ng mL-1, respectively. Hence, it turned out that the aptasensor strategy can be a promising candidate for developing a newly fluorescence assay for the simultaneous quantitative detection of multiple tumor markers in matrix samples by changing the corresponding sequences of aptamer and fluorescent signal probe, which has great potential for the screening of early cancer.

Effects of Clostridium butyricum as an Antibiotic Alternative on Growth Performance, Intestinal Morphology, Serum Biochemical Response, and Immunity of Broilers.

The current study aimed to investigate the effects of Clostridium butyiricum on growth performance, intestinal morphology, serum biochemical response, and immunity in broiler chickens. A total of 330 commercial one-day-old, mixed-sex Ross 308 broilers were randomly divided into five treatment groups with six replicates per group. The broilers were fed the basal diet (CON), the basal diet with 150 mg/kg of aureomycin (AM), the basal diet with C. butyricum at 2 × 108 CFU/kg (CBL), the basal diet with C. butyricum at 4 × 108 CFU/kg (CBM), and the basal diet with C. butyricum at 8 × 108 CFU/kg (CBH). Results showed that the final body weight (BW) (p < 0.01; p < 0.05), ADG from day 22 to 39 (p < 0.05), and ADG from day 1 to 39 (p < 0.01; p < 0.05) were improved in a linear and quadratic response with the inclusion of C. butyricum. There were no differences in feed conversion rate (FCR) among all groups (p > 0.05). Supplementation with C. butyricum quadratically reduced the crypt depth at day 21 (p < 0.01), linearly improved the villus height in the jejunum at day 39 (p < 0.001), and linearly and quadratically increased the villus height to crypt depth (V/C) ratio in the jejunum at day 21 (p < 0.01) and day 39 (p < 0.01; p < 0.001). Dietary C. butyricum affected the thymus index at day 21 and day 39 (linear, p < 0.01), and the bursa of Fabricius index at day 39 (quadratic, p < 0.05). Compared to the AM group, the serum urea contents were decreased (p < 0.05) but the IgG contents were increased in the CBL and CBH groups at day 21 (p < 0.01); in addition, serum albumin (ALB) concentrations in all the C. butyricum-supplemented groups (p < 0.01) and IgG concentrations in the CBM group were augmented at day 39 (p < 0.05). In conclusion, dietary C. butyricum could enhance growth performance by improving jejunal morphology and stimulating immunity organ development in broilers, and could be an alternative to antibiotics in poultry feeds.

Synthesis of Difluoroalkylated Benzofuran, Benzothiophene, and Indole Derivatives via Palladium-Catalyzed Cascade Difluoroalkylation and Arylation of 1,6-Enynes.

A novel and efficient method for the synthesis of difluoroalkylated benzofuran, benzothiophene, and indole derivatives via palladium-catalyzed aryldifluoroalkylation of 1,6-enynes with ethyl difluoroiodoacetate and arylboronic acids has been established. High reaction efficiency, mild conditions, broad substrate scope, and good functional group tolerance are the features of this protocol. Notablely, the resultant products can be smoothly converted into CF2-containing benzofurans, benzothiophenes and indoles through an isomerization process catalyzed by Fe(OTf)3.

Design and Development of a Novel Peptide for Treating Intestinal Inflammation.

Intestinal inflammatory disorders, such as inflammatory bowel disease (IBD), are associated with increased pro-inflammatory cytokine secretion in the intestines. Furthermore, intestinal inflammation increases the risk of enteric cancer, which is a common malignancy globally. Native anti-inflammatory peptides are a class of anti-inflammatory agents that could be used in the treatment of several intestinal inflammation conditions. However, potential cytotoxicity, and poor anti-inflammatory activity have prevented their development as anti-inflammatory agents. Therefore, in this study, we designed and developed a novel hybrid peptide for the treatment of intestinal inflammation. Eight hybrid peptides were designed by combining the active centers of antimicrobial peptides, including LL-37 (13-36), YW12D, innate defense regulator 1, and cathelicidin 2 (1-13) with thymopentin or the active center of thymosin alpha 1 (Tα1) (17-24). The hybrid peptide, LL-37-Tα1 (LTA), had improved anti-inflammatory activity with minimal cytotoxicity. LTA was screened by molecule docking and in vitro experiments. Likewise, its anti-inflammatory effects and mechanisms were also evaluated using a lipopolysaccharide (LPS)-induced intestinal inflammation murine model. The results showed that LTA prevented LPS-induced impairment in the jejunum epithelium tissues and infiltration of leukocytes, which are both histological markers of inflammation. Additionally, LTA decreased the levels of tumor necrosis factor-alpha, interferon-gamma, interleukin-6, and interleukin-1ß. LTA increased the expression of zonula occludens-1 and occludin, and reduced permeability and apoptosis in the jejunum of LPS-treated mice. Additionally, its anti-inflammatory effect is associated with neutralizing LPS, binding to the Toll-like receptor 4-myeloid differentiation factor 2 (TLR4/MD-2) complex, and modulating the nuclear factor-kappa B signal transduction pathway. The findings of this study suggest that LTA may be an effective therapeutic agent in the treatment of intestinal inflammation.